Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KB301 · 1 trial · 4 indications
The primary outcome will look at the safety and tolerability of KB301 through the collection and quantification of adverse events, physical examinations, vital signs and clinical laboratory tests.
| Arm | Type | Description |
|---|---|---|
| KB301 | ACTIVE_COMPARATOR | non-integrating HSV-1 vector expressing human type III collagen |
| Placebo | PLACEBO_COMPARATOR | sterile isotonic saline |
| Name | Type | Description |
|---|---|---|
| KB301 | BIOLOGICAL | non-integrating HSV-1 vector expressing human type III collagen |
| Placebo | OTHER | sterile isotonic saline |
Inclusion Criteria: 1. Male or female in good general health, as determined by the investigator, aged ≥18 and ≤75 at the time of consent (only females for Cohort 4) 2. Regions of suitable skin to be selected as Target Area(s), as determined by a physical examination conducted by the investigator du...
KB301 is an investigational therapy being developed for skin roughness, wrinkles, fine lines, and skin thickness. It is administered to treat superficial skin depressions. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
KB301 targets COL3A1, the gene that encodes human type III collagen. The therapy is designed to express human type III collagen (COL3) to address skin conditions. It is being studied for its potential effects on skin roughness and related dermatological indications.
KB301 is being developed by Krystal Biotech, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and efficacy of KB301 for dermatological indications. Krystal Biotech is publicly traded under the ticker symbol KRYS.
KB301 is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The ongoing Phase 1 trial is active but not recruiting participants, indicating that enrollment has been completed and the study is continuing.
KB301 is being evaluated in a Phase 1 clinical trial registered as NCT04540900. This study is a placebo-controlled trial investigating KB301 for the treatment of superficial skin depressions, including skin roughness, wrinkles, and fine lines. The trial is active but not recruiting and has an enrollment of 85 participants.
KB301 is a therapy that expresses human type III collagen (COL3). It is designed to deliver the COL3A1 gene to produce type III collagen in the skin. While KB301 is the drug product, COL3 refers to the collagen protein it is intended to generate.